# Amycretin Dosing Guide: Oral Daily and Weekly Subcutaneous Protocols
> Note: PeptIQ is not a medical provider. Amycretin is investigational. Early-phase doses are not a consumer titration chart. Educational content only.
Amycretin is Novo Nordisk's unimolecular long-acting GLP-1 and amylin receptor agonist — one molecule hitting both pathways CagriSema attacks with two drugs. That dual biology is why "amycretin dosage" is becoming a high-intent query beside orforglipron and eloralintide.
Novo has advanced both oral (once daily) and subcutaneous (once weekly) formulations toward Phase 3 obesity development based on early clinical data published in The Lancet.
Quick Answer: Amycretin Dosing Formats
| Format | Cadence | Early-phase dose anchors (public) |
|---|---|---|
| Subcutaneous amycretin | Once weekly | Dose-response exploration including 1.25 mg, 5 mg, and 20 mg maintenance-style exposures in Phase 1b/2a parts |
| Oral amycretin | Once daily | Early human study doses including 50 mg daily and higher (2×50 mg) over short windows |
Exact Phase 3 maintenance ladders will supersede these early maps when protocols publish.
Subcutaneous Results People Cite
In a Phase 1b/2a randomized study of adults with overweight or obesity (n=125 in public summaries):
| Exposure described | Approx. mean weight change | Approx. duration context |
|---|---|---|
| 1.25 mg | ~−9.7% | ~20-week style public summary |
| 5 mg | ~−16% | ~28-week style public summary |
| 20 mg | ~−22% | ~36-week style public summary |
| Matching placebo arms | slight gain (~+2%) | same windows |
Adverse events were predominantly gastrointestinal and mostly mild to moderate — class-consistent with incretin/amylin therapy when titrated.
Different press summaries sometimes quote alternate top-end figures depending on which analysis part they emphasize. Prefer the Lancet tables for citations.
Oral Amycretin: Why It Matters for SEO
Oral amycretin's first-in-human style readouts (EASD / company communications) reported roughly:
| Oral dose pattern | Approx. mean weight change | Duration |
|---|---|---|
| 50 mg once daily | ~−10% | ~12 weeks |
| 2×50 mg | ~−13% | ~12 weeks |
| Placebo | ~−1% | same |
Weight loss had not clearly plateaued by week 12 in early commentary — a classic "this will get more interesting with longer Phase 3" signal.
Compared with oral semaglutide, amycretin's dual agonist story + Novo's Phase 3 push makes it a direct competitor narrative to orforglipron (Lilly oral GLP-1) in search.
Amycretin vs CagriSema vs Eloralintide
| Amycretin | CagriSema | Eloralintide | |
|---|---|---|---|
| Design | One molecule: GLP-1 + amylin | Two molecules: sema + cagrilintide | Selective amylin agonist |
| Formats | Oral daily + SC weekly in development | Weekly combo injection story | Weekly SC |
| Early standout | Large % loss in small early SC cohorts | Large Phase 3 combo dataset | Phase 2 monotherapy ~9–20% |
Amycretin is not "better CagriSema" by default — it is a different product architecture that may simplify administration if Phase 3 confirms efficacy and tolerability.
Titration Philosophy (Educational)
Early programs used careful escalation because dual pathway agonism can stack GI effects. Until Phase 3 labels exist:
- Assume slow step-ups beat hero dosing
- Log nausea for 48–72 hours after each increase
- Protect protein (≥1.6 g/kg targets when appetite collapses)
- Keep resistance training non-negotiable
What Phase 3 Should Clarify
Novo communicated plans to start Phase 3 in adults with overweight/obesity after end-of-phase-2 regulatory discussions, with program initiation targeted around early 2026 in company timelines. Watch for:
- Final oral vs SC dose ladders
- 68–72+ week weight curves
- Discontinuation rates vs semaglutide / CagriSema benchmarks
- Whether oral amycretin needs food/water rules (orforglipron-style convenience is a competitive flashpoint)
FAQ
Q: What is the amycretin dose for weight loss?
A: There is no approved dose. Early SC exploration publicly highlighted 1.25 / 5 / 20 mg weekly-style exposures; oral work explored ~50 mg daily and higher short-term. Phase 3 will define labeled titration.
Q: Is amycretin a peptide injection or a pill?
A: Both formats are in development — once-weekly subcutaneous and once-daily oral.
Q: Is amycretin the same as CagriSema?
A: No. CagriSema combines two drugs. Amycretin is a single dual agonist molecule.
Q: How does amycretin compare to retatrutide?
A: Different receptor map. Retatrutide is GLP-1/GIP/glucagon. Amycretin is GLP-1/amylin. Compare trials, not vibes.
Bottom Line
Amycretin dosing is a two-track story: early SC weekly exposures up through ~20 mg with very large mean losses in small cohorts, plus oral daily doses in the ~50 mg range over short windows — now heading into Phase 3. Track pathway literacy (GLP-1 + amylin in one molecule) and wait for the formal ladders.
Download PeptIQ to log oral daily or weekly injectable metabolic protocols in one place.
Educational content only. Not medical advice.
